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Clinical and Ultrasonographic Monitoring of Response
to Adalimumab Treatment in Rheumatoid Arthritis
ANNAMARIA IAGNOCCO, EMILIO FILIPPUCCI, CHIARA PERELLA, FULVIA CECCARELLI, EMANUELE
CASSARÀ, CRISTIANO ALESSANDRI, EMANUELA SABATINI, WALTER GRASSI, and GUIDO VALESINI
ABSTRACT. Objective. To evaluate by clinical, laboratory, and sonographic assessment the effects of adalimumab
therapy in patients with rheumatoid arthritis (RA) over 24 months of treatment.
Methods. Twenty-five patients with RA were commenced on adalimumab therapy. Before the begin-
ning of the therapy (Time 0) and after 3 (T1), 12 (T2), and 24 (T3) months we evaluated erythrocyte
sedimentation rate, C-reactive protein, physician and patient visual analog scale for disease activity,
number of tender and swollen joints, Health Assessment Questionnaire, and Disease Activity Score in
28 joints. In addition, musculoskeletal ultrasound (US) was performed bilaterally in the 2nd and 5th
metacarpophalangeal, 3rd interphalangeal, wrist, and knee joints and in the tendon sheaths and bursae
of those areas. A semiquantitative score (0–3) was used to indicate the presence of a localized inflam-
matory process and/or structural damage. The summed total was used as an indicator of global change
in each joint (single joint score). The sum of the single joint scores was used as an indicator of overall
polyarticular involvement in each patient (total score).
Results. Patients who did not submit to the planned examinations strictly on time were excluded from
the study. Then 25 patients were examined at T0 and T1, 20 at T2, and 9 at T3. All clinical and labora-
tory measures as well as the US scores were significantly reduced during the followup.
Conclusion. A positive response to treatment with adalimumab was demonstrated by clinical, laborato-
ry, and US evaluation by both short- and longterm followup. (First Release Nov 15 2007; J Rheumatol
2008;35:35–40)
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Rheumatoid arthritis (RA) is a chronic polyarthritis character-
ized by aggressive synovitis determining progressive joint
destruction1. The inflammatory process results in permanent
damage with consequent loss of physical function and anky-
losis. In the progression of the disease a key role is played by
tumor necrosis factor-α (TNF-α), which represents the target
of recent pharmacological strategies, such as the biologic drug
adalimumab, aiming to limit its activities2. Adalimumab is
used for its capacity to bind specifically to TNF-α and block
its interaction with the p55 and p75 cell-surface TNF recep-
tors, determining inhibition of TNF-α3-7.
Musculoskeletal ultrasonography (US) is a useful imaging
technique in the diagnosis and followup of rheumatic dis-
eases. It is able to demonstrate the presence of inflammation
in the joint and periarticular soft tissues as well as to show the
presence of structural damage8. Using US it is possible to
detect different changes related to synovitis, tenosynovitis,
bursitis, bone erosions, and cartilaginous abnormalities start-
ing in early disease9. The application of power Doppler US
provides an accurate estimate of synovial perfusion, which
has been shown to correlate with the presence of active syn-
ovitis10. Only a few studies about US evaluation of the
response to biologic therapy have been published11-18. The
results have, however, underlined the key role played by US
as a reliable imaging modality in evaluation of the antiinflam-
matory effects of biologic therapy.
We assessed the response to adalimumab therapy by means
of clinical, laboratory, and US indices of disease activity over
2 years of treatment.
MATERIALS AND METHODS
Twenty-five consecutive patients, 21 women and 4 men, with RA fulfilling
the American Rheumatology Association diagnostic criteria were studied.
Patients were receiving adalimumab (40 mg subcutaneously, once every 2
wks) plus methotrexate (10–15 mg weekly) and/or hydroxychloroquine (400
mg daily) and/or cyclosporine A (3–5 mg/kg daily) and/or leflunomide (20
mg/daily) and nonsteroidal antiinflammatory drugs (diclofenac 50–100 mg
daily or indomethacin 50–100 mg daily or nimesulide 100–200 mg daily) and
steroids (methylprednisolone 4–8 mg daily). The mean age was 55.6 years
(range 20.16–72.25) with mean disease duration of 11 years (range 3.8–30).
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US, clinical, and laboratory examinations were performed just before
starting adalimumab (Time 0) and after 3, 12, and 24 months (T1, T2, and T3,
respectively). Patients who did not submit to the planned examinations invari-
ably and strictly on time were excluded from the study. For this reason with
respect to 25 patients examined at T0 and T1, the number reduced to 20 at T2
and to only 9 at T3.
Our study was carried out at the Rheumatology Unit of La Sapienza
University in Rome, Italy, and was conducted in compliance with good clini-
cal practices, following the routine monitoring procedures performed in our
unit for patients with arthritis.
Clinical and laboratory evaluation. The clinical and laboratory values meas-
ured at T0, T1, T2, and T3 are listed in Table 1. Clinical evaluation was per-
formed by an experienced rheumatologist (FC) who was blinded to the US
assessment and the laboratory data.
US examination. The joints, periarticular structures, and measures studied by
US are listed in Table 1. The joints evaluated were chosen because they are
commonly involved in RA and they can be reliably assessed by US. The US
examination was performed using a Philips/HP Image Point HX machine with
a 10 MHz linear probe for knee joints and a 14 MHz probe for the hands and
wrists. In addition, power Doppler US was used with the following settings:
frequency 7 MHz, PRF varying from 700 to 1000 (according to the joint stud-
ied), gain 18–30 dB, low filter. The US study was performed by an experi-
enced rheumatologist sonographer (AI) who was blinded to the clinical and
laboratory findings.
Using a multiplanar scanning technique19,20, the presence of any inflam-
mation-related change in the joints and/or in the adjacent tendon sheaths and
bursae (effusion, synovial proliferation, increased local perfusion by power
Doppler US) was assessed. The presence of permanent joint damage (bone
and cartilaginous erosions) was also registered. The changes within each
articular and periarticular structure were recorded as being present in accord
with definitions in the literature21 and registering the highest score during the
multiplanar scanning evaluation. For all the changes a semiquantitative score
(0–3) was used for each structure examined, where 0 was to indicate the
absence of any change and 1 to 3 the presence, respectively, of a slight, mod-
erate, and severe change (single-measure score). The subsequent summed
total was used as an indicator of global change at each timepoint in each joint
(single-joint score). The sum of the single-joint scores was used as an indica-
tor of overall polyarticular involvement in each patient (total score).
Statistical analysis. Data were reported as median values with the interquar-
tile ranges in cases of variables with nonstandard distribution.
Data were analyzed using McNemar test and Wilcoxon paired test.
Statistical significance was taken at a p value < 0.05.
RESULTS
Our results are reported in Tables 2 and 3 and in Figures 1 and 2.
Erythrocyte sedimentation rate (ESR) fell significantly
from a median value of 34, to 24 (p < 0.0001) at T1, 25 (p <
0.0001) at T2, and 20 (p < 0.003) at T3. C-reactive protein
(CRP) also decreased, from a median value of 19.9 at T0 to
3.6 at T1 (p < 0.0001), 3.5 at T2 (p < 0.0003), and 3.5 at T3
(p < 0.01).
Median Health Assessment Questionnaire (HAQ) values
fell significantly, from 1.62 at baseline to 0.62 at 3 months (p
< 0.0001), 0.5 at 12 months (p < 0.0001), and 0.5 at 24 months
(p < 0.0001).
The number of tender joints changed significantly, from a
median of 15 at T0 to 2 at T1 (p < 0.0001), 2 at T2 (p <
0.0001), and 1 at T3 (p < 0.003). Similarly, the median num-
ber of swollen joints also fell significantly, from 9 at baseline
to 0 at T1 (p < 0.0001), 0 at T2 (p < 0.0001), and 0 at T3 (p <
0.007).
The median physician VAS decreased significantly, from
67 at T0 to 20 at T1 (p < 0.0001), 19 at T2 (p < 0.0001), and
20 at T3 (p < 0.007). Also the median patient VAS decreased
significantly from 65 at T0 to 21 at T1 (p < 0.0001), 15 at T2
(p < 0.0001), and 15 at T3 (p < 0.007).
The mean Disease Activity Score for 28 joints (DAS28)
fell significantly, from 6.3 at baseline to 3.5 at 3 months (p <
0.0001), 2.8 at 12 months (p < 0.0001), and 3 at 24 months (p
< 0.003).
US showed a significant reduction in the total score during
the followup, from T0 to T1 (p < 0.0001), T2 (p < 0.0001),
and T3 (p < 0.0001). In particular, the median total score was
11 (range 4–19) at baseline and decreased to 6.1 (range 0–14)
at T1, 5.8 (range 1–17) at T2, and 6.1 (range 1–15) at T3.
During the whole 24 months’ followup, even the single-joint
scores decreased significantly in most cases, ranging from p <
0.0001 to p < 0.03. The only nonsignificant reduction was
present at T3 for the third proximal interphalangeal joint score
and for the second metacarpophalangeal joint score.
As reported in Figure 1, the reduction of the total score
during the followup corresponded to a similar and parallel
decrease in DAS28.
In Figure 2, a reduction of joint effusion in the knee (A and
B) and in the wrist (C and D) is shown after 3 months of treat-
ment (T1).
DISCUSSION
The use of biologic agents as a treatment of RA has increased
markedly over the last few years and it has been the subject of
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Table 1. Clinical, laboratory, and ultrasound (US) measures studied.
Clinical and laboratory measures
Erythrocyte sedimentation rate
C-reactive protein
Patient visual analog score (VAS)
Physician VAS
Health Assessment Questionnaire
Number of tender joints
Number of swollen joints
Disease Activity Score 28
Joints and periarticular structures studied by US (bilaterally)
II metacarpophalangeal (MCP)
V MCP
III proximal interphalangeal
Wrist
Knee
II-III-V digits flexor tendons
Wrist flexor and extensor tendons
Gastrocnemius-semimembranosus bursa
US measures evaluated (score 0–3)
Synovial membrane: proliferation/thickening/hyperperfusion (power
Doppler)
Synovial fluid: effusion
Bone and cartilage: erosions
Tendon sheath and gastrocnemius-semimembranosus bursa: local
effusion/synovial proliferation ± hyperperfusion
 Journal of Rheumatology
The on October 31, 2016 - Published by www.jrheum.orgDownloaded from 
increasing interest for the documented evidence of positive
effects in patients who are nonresponders or partial responders
to disease modifying antirheumatic drug therapy22-26.
Over the last few decades the application of US in the
assessment of joint and soft tissues changes in rheumatic dis-
eases has progressively widened. Recently, the use of Doppler
and the technological improvement of US equipment have
further shown the usefulness of this diagnostic tool in the
evaluation of arthritis27,28. In particular, some recent articles
have documented the reliability of gray-scale US and
power/color Doppler to monitor the response to biologic ther-
apy in RA and spondyloarthritis17. In the first publication
about this topic, Hau, et al demonstrated a significant reduc-
tion in the synovial perfusion with power Doppler US at the
level of the second metacarpophalangeal joint15 in 5 patients
with RA treated with etanercept. Subsequently, a decrease in
power Doppler US signal within the Achilles tendon insertion
in 2 patients treated with infliximab was reported11. A reduc-
tion was shown in the signs of synovitis by gray-scale and
power Doppler US in hand joints of patients with RA treated
with infliximab12. Then, a relevant decrease in the synovial
perfusion in hand and wrist joints in patients with RA treated
with etanercept was demonstrated19. In patients with RA treat-
ed with methotrexate and infliximab or placebo a reduction in
inflammation and retardation of joint destruction in those who
received infliximab was documented by both radiography and
US13.A significant decrease in power Doppler signal and thin-
ning of the synovial membrane in patients with RA and psori-
atic arthritis treated with etanercept has been described17.
Finally, we have also recently documented the response to
adalimumab therapy in RA, demonstrating a reduction in the
synovial perfusion by power Doppler US over 12 weeks of
treatment18.
To our knowledge, this study represents the first attempt to
investigate by clinical, laboratory, and US assessment the
short- and longterm effects of adalimumab therapy on multi-
ple measures in various joints in patients with RA. Until now
the response to biologic treatment had been documented in
very few studies, which were limited by the number of
patients evaluated, the low number of joints examined, and the
short period of followup11-18.
We observed a good short- and longterm response to treat-
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Table 2. Results at T0, T1, T2, and T3. Data are expressed as median values, interquartile, and ranges (p value).
T0 T1 T2 T3
No. of patients 25 25 20 9
ESR 34;4–96 24;2–56 25; 3–97 20; 8–30
(< 0.0001) (0.0001) (0.003)
CRP 19.9; 3–227 3.6; 3–112 3.5; 2–98 3.5; 3–84
(0.0001) (0.0003) (0.01)
HAQ 1.62; 0.12–2.87 0.62; 0–2.87 0.5; 0–2.5 0.5; 0–2
(< 0.0001) (< 0.0001) (0.003)
No. of tender joints 15; 3–26 2; 0–12 2; 0–25 1; 0–10
(< 0.0001) (< 0.0001) (0.003)
No. of swollen joints 9; 1–24 0; 0–8 0; 0–11 0; 0–8
(< 0.0001) (< 0.0001) (0.007)
Physician VAS 67; 25–94 20; 0–69 19; 0–94 20; 0–40
(< 0.0001) (< 0.0001) (0.007)
Patient VAS 65; 21–94 21; 0–81 15; 0–76 15; 5–40
(< 0.0001) (< 0.0001) (0.007)
DAS28 6.3; 4.2–7.9 3.5; 0–6.5 2.8; 0–6.9 3; 1.6–4.8
(< 0.0001) (< 0.0001) (0.003)
US scores
2; 0–6 2; 0–5 2; 1–5
knee + Baker’s cyst 4;1–7 (< 0.0001) (0.0001) (0.006)
2; 0–5 2; 0–5 1; 0–4
wrist + flexor and extensor tendons 3; 0–6 (<0.0001) (0.0002) (0.003)
1; 0–2 1; 0–2 0; 0–7
5th MCP + flexor tendons 1; 0–4 (< 0.0001) (< 0.0001) (0.02)
0; 0–3 0; 0–1 1; 0–3
3rd PIP + flexor tendons 0.5; 0–3 (0.03) (< 0.0001) NS
1; 0–3 1; 0–6 1; 0–4
2nd MCP + flexor tendons 1; 0–4 (0.0004) (0.004) NS
Total Score 11; 4–19 6.1; 0–14 5.8; 1–17 6.1; 1–15
(< 0.0001) (< 0.0001) (< 0.0001)
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; VAS:
visual analog scale; DAS: Disease Activity Score; US: ultrasound; MCP: metacarpophalangeal; PIP: proximal
interphalangeal.
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ment by clinical, laboratory, and US evaluation. In particular,
referring to US, the reduction in the total score as well as in
the single-joint scores attests to the positive effects of the ther-
apy both systemically and locally. The short-term response to
adalimumab appeared immediately evident in all patients and
was confirmed after 1 year. The positive trend was subse-
quently maintained after 2 years in the 9 subjects in which the
followup was performed. The importance of these data is con-
firmed by a parallel and significant reduction in all the clini-
cal and laboratory indices of disease activity.
The low number of patients in whom the longterm fol-
lowup was performed represents a limitation of our study,
38 The Journal of Rheumatology 2008; 35:1
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Table 3. Ultrasound (US) variations of the single measure scores at T0, T1, T2, and T3. Significance values are in relation to baseline values (T0; McNemar
test). Number of joints out of the total assessed that had a detectable US abnormality at T0, T1, T2, and T3 is reported. Values refer to the number of joints
in which the different findings are present.
No. Joints Involved (%) Ultrasonographic Changes T0 T1 p T2 p T3 p
Knee joint Synovial proliferation 27 (54) 20 (40) NS 16 (42) NS 5 (28) < 0.05
Power Doppler 10 (20) 4 (8) NS 3 (8) NS 2 (11) NS
Joint effusion 26 (52) 10 (20) 0.004 8 (21) 0.005 6 (33) NS
Erosions 37 (74) 40 (80) NS 34 (89) NS 14 (78) NS
Gastrocnemius-semimebranosus Baker’s cyst 12 (24) 6 (12) NS 7 (18) NS 7 (39) NS
bursa
Wrist joint Synovial proliferation 37 (74) 22 (44) 0.008 18 (47) 0.0009 6 (33) 0.004
Power Doppler 28 (56) 6 (12) 0.0001 7 (18) NS 1 (6) 0.002
Joint effusion 29 (58) 6 (12) 0.0001 7 (18) 0.001 3 (17) 0.001
Erosions 43 (86) 44 (88) NS 39 (103) 0.003 18 (100) NS
Wrist flexor and extensor Tendon sheath distension 24 (48) 3 (6) 0.0001 6 (16) 0.0008 6 (33) NS
tendons
3rd PIP joint Synovial proliferation 8 (16) 1 (2) 0.04 2 (5) NS 1 (6) NS
Power Doppler 0 (0) 0 (0) NS 2 (5) NS 0 (0) NS
Joint effusion 10 (20) 3 (6) NS 2 (5) NS 2 (11) NS
Erosions 19 (38) 20 (40) NS 19 (50) NS 8 (44) NS
3rd finger flexor tendons Tendon sheath distension 6 (12) 1 (2) NS 2 (5) NS 0 (0) NS
5th MCP joint Synovial proliferation 17 (34) 2 (4) 0.001 2 (5) 0.002 3 (17) NS
Power Doppler 2 (4) 0 (0) NS 0 (0) NS 0 (0) NS
Joint effusion 23 (46) 4 (8) 0.0001 0 (0) 0.0001 2 (11) 0.02
Erosions 31 (62) 32 (64) NS 26 (68) NS 7 (39) NS
5th finger flexor tendons Tendon sheath distension 7 (14) 0 (0) 0.02 0 (0) 0.04 0 (0) NS
2nd MCP joint Synovial proliferation 17 (34) 5 (10) 0.04 5 (13) 0.006 2 (11) NS
Power Doppler 4 (8) 0 (0) NS 2 (5) NS 1 (6) NS
Joint effusion 17 (34) 3 (6) 0.003 2 (5) 0.004 5 (28) NS
Erosions 28 (56) 29 (58) NS 23 (61) NS 11 (61) NS
2nd finger flexor tendons Tendon sheath distension 8 (16) 3 (6) NS 1 (3) NS 0 (0) NS
NS: nonsignificant.
Figure 1.A. Total joint scores by US. The sum of single-joint scores was used as an indicator of overall polyartic-
ular involvement in each patient and expressed as total score. p < 0.01, T0 compared to T1, T2, T3. B. DAS28
scores. p < 0.01, T0 compared to T1, T2, T3. Median, quartiles, range, and extreme values are shown. o: outliers.
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although it is an interesting finding that needs further confir-
mations on larger cohorts of patients.
The fact that we have not examined by US some frequent-
ly involved articular sites such as the foot and the second
proximal interphalangeal joints represents another limitation
of our study. More extended evaluations on multiple joints are
recommended.
An interesting finding was that US is a valuable tool for
analysis of the response to treatment in RA. This diagnostic
tool has many advantages over other techniques and proce-
dures and by clinical indices of disease activity. Indeed, it is
characterized by low cost, noninvasiveness, and the possibili-
ty of a contemporaneous assessment of many different joints,
making it possible to analyze both inflammatory and structur-
al changes29-31. We documented a close relationship between
US findings and the commonly used clinical and serological
indices of disease activity, confirming and strengthening the
case for using US as one of the investigations of choice in the
monitoring of biologic therapy in RA32-36.
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